Bull
$89.49
シナリオ価格
$90.650
-0.580 (-0.64%)終値時点
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.
TD Cowen
$110
2026-08-28
TD Cowen
2026-08-28
目標株価
$110
Needham
$114
2026-08-27
Needham
2026-08-27
目標株価
$114
UBS
$100
2026-07-28
UBS
2026-07-28
目標株価
$100
Evercore ISI
$105
2026-07-06
Evercore ISI
2026-07-06
目標株価
$105
BofA
$95
2026-06-12
BofA
2026-06-12
目標株価
$95
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Medtronic Reports Strong Q1 FY27 Results with Revenue Growth

Medtronic's Strategic Investment in Pi-Cardia

Medtronic's Strategic Investment in Pi-Cardia

Apple CEO Transition and Market Dynamics

Stocks Open Lower, Energy Sector Leads Amid Geopolitical Tensions
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.
23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。